Yousif Capital Management LLC Sells 2,855 Shares of Gilead Sciences, Inc. $GILD

Key Points

• Yousif Capital Management LLC reduced its stake in Gilead Sciences by 1.9%, selling 2,855 shares, leaving it with 144,883 shares valued at approximately $16.06 million.
• CEO Daniel O'Day sold 10,000 shares of Gilead at $111.66 each, resulting in a total transaction of $1.12 million, which reduced his ownership by 1.66%.
• Analysts have upgraded Gilead Sciences, with multiple research firms raising their ratings and price targets, reflecting a growing confidence in the company's performance.

Yousif Capital Management LLC lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 144,883 shares of the biopharmaceutical company's stock after selling 2,855 shares during the period. Yousif Capital Management LLC's holdings in Gilead Sciences were worth $16,063,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of GILD. Brighton Jones LLC grew its position in Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after acquiring an additional 2,450 shares during the last quarter. Bison Wealth LLC bought a new position in Gilead Sciences in the fourth quarter valued at about $215,000. GAMMA Investing LLC grew its position in Gilead Sciences by 24.9% in the first quarter. GAMMA Investing LLC now owns 22,760 shares of the biopharmaceutical company's stock valued at $2,550,000 after acquiring an additional 4,532 shares during the last quarter. Salem Investment Counselors Inc. grew its position in Gilead Sciences by 345.5% in the first quarter. Salem Investment Counselors Inc. now owns 490 shares of the biopharmaceutical company's stock valued at $55,000 after acquiring an additional 380 shares during the last quarter. Finally, Stock Yards Bank & Trust Co. bought a new position in Gilead Sciences in the first quarter valued at about $242,000. Institutional investors own 83.67% of the company's stock.

Insider Transactions at Gilead Sciences

In other news, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the transaction, the chief executive officer directly owned 591,203 shares of the company's stock, valued at $66,013,726.98. This represents a 1.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the sale, the insider owned 114,168 shares of the company's stock, valued at $13,532,333.04. This trade represents a 19.70% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 77,000 shares of company stock valued at $8,853,430 over the last ninety days. 0.27% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research firms have issued reports on GILD. Daiwa America upgraded Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective for the company in a research note on Friday, July 25th. Daiwa Capital Markets raised Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price objective for the company in a research note on Tuesday, August 19th. Royal Bank Of Canada upped their price objective on Gilead Sciences from $98.00 to $100.00 and gave the company a "sector perform" rating in a research note on Wednesday, October 8th. Finally, Weiss Ratings reaffirmed a "buy (b)" rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $118.08.

Gilead Sciences Price Performance

Shares of GILD opened at $117.18 on Monday. Gilead Sciences, Inc. has a 52-week low of $84.17 and a 52-week high of $121.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The business's 50 day moving average price is $114.65 and its two-hundred day moving average price is $110.25. The firm has a market cap of $145.40 billion, a PE ratio of 23.34, a price-to-earnings-growth ratio of 0.80 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same period in the previous year, the firm earned $2.01 earnings per share. The company's revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences's dividend payout ratio is presently 62.95%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.